| Life & Brain–BC Platforms: genomic software tools, 201912– collab using BC Platforms solutions for genotyping services |
2019-12-06 |
| Life Sciences Partners–BMS: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor BMS |
2020-03-10 |
| Life Sciences Partners–EQT: investment, 202111–202202 acquisition €450m upfront with €112.5m in cash + €337.5m in shares plus €25m milestones |
2021-11-10 |
| Life Sciences Partners–EU (govt): investment, 202003 final closing totalling €600m of LSP 6 fund incl investor EIF |
2020-03-10 |
| Life Sciences Partners–Otsuka: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor Otsuka Pharmaceutical |
2020-03-10 |
| Life Sciences Partners–SEVERAL: investment, 202003 final closing €600m of LSP 6 fund with investors incl BMS + Otsuka + EIF |
2020-03-10 |
| Life Sciences Partners–SEVERAL: investment, 202103 IPO $120m of SPAC European Biotech Acquisition Corp at Nasdaq |
2021-03-18 |
| Lilly–Nordic Bioscience: antidiabetic, 201706– strategic collab $55m upfront + milestones + royalties ww rights to develop DACRAs from KeyBioscience |
2017-06-08 |
| LimmaTech Biologics–SEVERAL: investment, 202310 financing round Series A $37m co-led by Adjuvant Capital + AXA IM Alts + Novo REPAIR Impact Fund |
2023-10-09 |
| Lobsor–Stada: investment, 202009 acquisition of Lobsor Pharmaceuticals AB by Stada/Britannia |
2020-09-01 |
| Lundbeck–Enamine: chemical compound libraries, 201903– supply expansion discovery chemistry services by Enamine |
2019-03-26 |
| Lundbeck–Genedata: bioinformatics, 202002 supply existent Lundbeck is existing customer of Genedata |
2020-02-26 |
| Lundbeck–IBM: healthcare informatics, 201701– collab using Watson Health technology + cloud to advance CNS drug development |
2017-01-25 |
| Lundbeck–LeadXPro: drug discovery services, 201910– collab structural proteomics services using X-ray + cryo-EM for small molecule drug discovery |
2019-10-07 |
| Lysogene–Novo Group: investment, 201702 existing investor Novo A/S |
2017-02-08 |
| Lytix Biopharma–SEVERAL: investment, 201704 private placement NOK60m incl NOK6m from Norwegian Cancer Society |
2017-04-20 |
| Macrophage Pharma–Aglaia: investment, 201701 financing round Series A totalling £9m incl co-investors Novo Seeds + Aglaia |
2017-01-09 |
| Macrophage Pharma–Chroma Therapeutics: cancer immunotherapy, 201701 acquisition of ESM technology w discovery stage theapeutic assets by Macrophage |
2017-01-09 |
| Macrophage Pharma–Merck (DE): investment, 201708 financing round Series A extension with new investor Merk Ventures |
2017-08-23 |
| Macrophage Pharma–Novo Group: investment, 201701 financing round Series A totalling £9m incl co-investors Novo Seeds + Aglaia |
2017-01-09 |
| Macrophage Pharma–SEVERAL: investment, 201701 financing round Series A £9m led by CRT Pioneer Fund + incl Novo Seeds + Aglaia |
2017-01-09 |
| Macrophage Pharma–Sixth Element Capital: investment, 201701 financing round Series A totalling £9m incl lead investor CRT Pioneer Fund |
2017-01-09 |
| MatTek–Cellink: investment, 202103– acquisition $68m net of cash/debt with $54.4m in cash + $13.6m in shares ANNOUNCED |
2021-03-10 |
| Medicomp–KLIFO: investment, 2019 acquisition of Medicomp GmbH by KLIFO A/S |
2019-01-01 |
| Medicxi Ventures–Alphabet: investment, 201706 closing totalling $300m of MG1 fund incl cornerstone investors EIF + Novartis + Verily |
2017-06-15 |
| Medicxi Ventures–EU (govt): investment, 201706 closing totalling $300m of MG1 fund incl cornerstone investors EIF + Novartis + Verily |
2017-06-15 |
| Medicxi Ventures–JnJ: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Medicxi Ventures–Novartis: investment, 201706 closing totalling $300m of MG1 fund incl cornerstone investors EIF + Novartis + Verily |
2017-06-15 |
| Medicxi Ventures–Novartis: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Medicxi Ventures–SEVERAL: investment, 201706 closing $300m of MG1 fund incl cornerstone investors EIF + Novartis + Verily |
2017-06-15 |
| Medicxi Ventures–SEVERAL: investment, 201907 closing €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| MediServ–KLIFO: investment, 2020 acquisition of MediServ by KLIFO A/S |
2020-01-01 |
| Medivir–BioCity (GB): compound management, 201708– supply service Medivir outsources compound management to BioAscent |
2017-08-23 |
| Medivir–Karo Pharma: investment, 201611–201612 acquisition of BioPhausia AB (Nordic Brands) for SEK908m cash+debt free in cash net SEK868m |
2016-11-01 |
| Medivir–Tetralogic Pharmaceuticals: cancer drugs, 201611 acquisition of remetinostat + birinapant + all related IP + data by Medivir |
2016-11-02 |
| Merck (US)–Agilent: molecular companion diagnostics, 201906 collab existent developm of PD-L1 IHC 22CR pharmDx for use with Keytruda |
2019-06-11 |
| Merus–Genedata: bioinformatics, 202002 supply existent Merus is existing customer of Genedata |
2020-02-26 |
| Metagenomi–Novo Group: investment, 202201 financing round Series B totalling $175m incl new + co-investor Novo Holdings A/S |
2022-01-25 |
| Metagenomi–SEVERAL: investment, 202201 financing round Series B $175m co-led by PFM Health Sciences + Farallon Capital Mgt + NN |
2022-01-25 |
| Microbiotica–Flerie Invest: investment, 202203 financing round Series B totalling £50m incl new + co-lead investor Flerie Invest |
2022-03-07 |
| Microbiotica–SEVERAL: investment, 202203 financing round Series B £50m co-led by Tencent + Flerie Invest |
2022-03-07 |
| MicrofluidX–SEVERAL: investment, 202212 financing round £3.3m with Longwall Ventures + UKI2S + JB Ugland Venture + Puffin Point + Esco LifeSciences |
2022-12-08 |
| Milestone Pharmaceuticals–Forbion: investment, 201810 financing round private totalling $80m incl existing + co-investor Forbion |
2018-10-25 |
| Milestone Pharmaceuticals–Novo Group: investment, 201708 financing round Series C totalling $55m incl lead investor Novo Holdings |
2017-08-01 |
| Milestone Pharmaceuticals–Novo Group: investment, 201810 financing round private totalling $80m incl existing + co-investor Novo Holdings A/S |
2018-10-25 |
| Milestone Pharmaceuticals–SEVERAL: investment, 201708 financing round Series C $55m led by Novo Holdings + incl Forbion et al |
2017-08-01 |
| Milestone Pharmaceuticals–SEVERAL: investment, 201810 financing round private $80m led by RTW Investments |
2018-10-25 |
| Mind the Byte–Prosilico: drug discovery + development software, 201711– collab co-promotion + product integration |
2017-11-15 |
| Mind the Byte–SEVERAL: investment, 201801– financing round €3m (1/3 of company) to finance acquisition of Intelligent Pharma PLANNED |
2018-01-11 |
| Minervax–Adjuvant Capital: investment, 202212 financing round totalling €22m incl exisiting + co-investor Adjuvant Capital |
2022-12-15 |
| Minervax–Bellevue: investment, 202212 financing round totalling €22m incl new + co-lead investor Pureos Bioventures |
2022-12-15 |
| Minervax–EU (govt): credit, 202212 loan facility €50m from EIB |
2022-12-15 |
| Minervax–LF Investment: investment, 202212 financing round totalling €22m incl exisiting + co-investor LF Investment |
2022-12-15 |
| Minervax–Novo Group: investment, 2018 investment €3.6m by Novo REPAIR Impact Fund |
2018-12-31 |
| Minervax–Novo Group: investment, 202212 financing round totalling €22m incl exisiting + co-investor Novo REPAIR Impact Fund |
2022-12-15 |
| Minervax–Sanofi: investment, 202212 financing round totalling €22m incl exisiting + co-investor Sanofi Ventures |
2022-12-15 |
| Minervax–SEVERAL: investment, 202212 financing round €22m co-led by Trill Impact Ventures + Pureos Bioventures |
2022-12-15 |
| Minervax–Sunstone Life Science: investment, 202212 financing round totalling €22m incl exisiting + co-investor Sunstone Life Science Ventures |
2022-12-15 |
| Minervax–Sweden (govt): investment, 202212 financing round totalling €22m incl exisiting + co-investor Industrifonden |
2022-12-15 |
| Minervax–Trill Impact: investment, 202212 financing round totalling €22m incl new + co-lead investor Trill Impact Ventures |
2022-12-15 |
| Minervax–Wellington Partners: investment, 202212 financing round totalling €22m incl exisiting + co-investor Wellington Partners |
2022-12-15 |
| MKS Instruments–Sartorius: investment, 201704 acquisition $72.5m of MKS Instruments AB (Umetrics) by Sartorius Stedim Biotech |
2017-04-03 |
| Mobidiag–Consilium: public relations, 201902 service existent by CSC |
2019-02-25 |
| Mobidiag–Hologic: investment, 202104– acquisition €600m in cash ANNOUNCED |
2021-04-08 |
| MOCON–AMETEK: investment, 201704– acquisition of MOCON Inc for aggregate enterprise value of $182m |
2017-04-17 |
| Modus Therapeutics–Huntsworth: public relations, 201704 service existent by Citigate Dewe Rogerson |
2017-04-24 |
| Modus Therapeutics–Odlander Fredrikson: investment, 201807 financing round totalling SEK140m incl SEK60m from new + lead investor HealthCap |
2018-07-13 |
| Modus Therapeutics–SEVERAL: investment, 201702 financing round SEK32m ($3.6m) from existing investors KDev + Östersjöstiftelsen + Praktikerinvest |
2017-02-20 |
| Modus Therapeutics–SEVERAL: investment, 201807 financing round SEK140m incl SEK60m from HealthCap + conversion convertible notes by shareholders |
2018-07-13 |
| Monocl–Definitive Healthcare: investment, 202010 acquisition of Monocl by Definitive Healthcare LLC |
2020-10-29 |
| Morphic–SEVERAL: investment, 201809 financing round Series B $80m co-led by Omega Funds + Novo Holdings |
2018-09-25 |
| MS-Omics–Clinical Microbiomics: investment, 202210 acquisition of MS-Omics ApS by Clinical Microbiomics A/S |
2022-10-17 |
| Muna Therapeutics–Golgi Neurosciences: investment, 202307 existent investment at time of spin-off of Golgi Neurosciences from Axxam |
2023-07-05 |
| myPOLS Biotec–Medix Biochemica: investment, 202202 acquisition 100% of myPOLS Biotec GmbH by Medix Biochemica |
2022-02-01 |
| Nab Labs (FI)–Eurofins: investment, 201706 acquisition of Nab Labs Group Oy by Eurofins |
2017-06-01 |
| Nanoform–Coulter Partners: recruitment services, 202001 supply service placement of Sally Langa as new head of US Sales at Nanoform |
2020-01-21 |
| Nanoform–Notch Communications: public relations, 201907 service existent by Notch |
2019-07-10 |
| Nanoform–SEVERAL: investment, 201907 private placement €10m incl Ilmarinen Mutual Pension Insurance + Mandatum Life Insurance |
2019-07-03 |
| Nanoform–SEVERAL: investment, 202103 directed placing €40m with 5.634m new shares at €7.1/share to institution + qualified investors with 7% discount |
2021-03-09 |
| Nanoscribe–Cellink: investment, 202105 acquisition 100% of Nanoscribe Holding for preliminary €36.9m with €24.7m cash + €12.2m in Series B shares |
2021-05-19 |
| Nanovi–SEVERAL: investment, 201908 financing round DKK19m from existing investors |
2019-08-27 |
| Navinci Diagnostics–Beijer Ventures: investment, 202207 financing round Series A totalling SEK90m incl existing + co-investor Beijer Ventures AB |
2022-07-12 |
| Navinci Diagnostics–Landegren Gene Technology: investment, 202207 financing round Series A totalling SEK90m incl existing + co-investor LGT |
2022-07-12 |
| Navinci Diagnostics–Nexttobe: investment, 202207 financing round Series A totalling SEK90m incl existing + co-investor Nexttobe AB |
2022-07-12 |
| Navinci Diagnostics–Segulah Medical Acceleration: investment, 202207 financing round Series A totalling SEK90m incl new + lead investor SMA |
2022-07-12 |
| Navinci Diagnostics–SEVERAL: investment, 202207 financing round Series A SEK90m led by new investor Segulah Medical Acceleration |
2022-07-12 |
| NBE Therapeutics–Novo Group: investment, 201806 financing round Series B CHF20m extension by Novo Holdings bringing total Series B to CHF40m |
2018-06-28 |
| Nebion–Qlucore: genomic software tools, 201801– collab integration of Qlucore Omics Explorer s/w + Genevestigator s/w for gene expression analysis |
2018-01-24 |
| NEC–Vaximm: cancer vaccines, 201911– collab + option agreem for personalised neoantigen cancer vaccines |
2019-11-12 |
| NEC–Vaximm: cancer vaccines, 202203 acquisition of all neoantigen cancer vaccines assets by NEC OncoImmunity |
2022-03-08 |
| Nerre Therapeutics–SEVERAL: investment, 201701 financing round Series B £23m from Fountain Healthcare + Forbion + Orbimed + Novo + Advent |
2017-01-05 |
| Neurogeneus–SEVERAL: investment, 202009 seed financing round £12m with Advent LS + DDF + F-Prime Capital + JJDC + LifeArc |
2020-09-11 |
| NeuroNova (SE)–Newron: investment, 2013 acquisition of NeuroNova by Newron |
2013-01-01 |
| NMD Pharma–ABP (NL): investment, 201803 financing round Series A totalling €38m incl new + lead investor Inkef Capital |
2018-03-23 |
| NMD Pharma–ABP (NL): investment, 202202 financing round totalling €35m incl existing + co-investor Inkef Capital |
2022-02-15 |
| NMD Pharma–Consilium: public relations, 202202 service existent by Consilium Strategic Communications |
2022-02-15 |
| NMD Pharma–Denmark (govt): investment, 201606 seed funding round totalling €3m from Lundbeckfonden Emerge + Novo Seeds + Capnova |
2016-06-13 |
| NMD Pharma–Jeito Capital: investment, 202202 financing round totalling €35m incl new + lead investor Jeito Capital |
2022-02-15 |
| NMD Pharma–Lundbeck: investment, 201606 seed funding round totalling €3m from Lundbeckfonden Emerge + Novo Seeds + Capnova |
2016-06-13 |
| NMD Pharma–Lundbeck: investment, 201803 financing round Series A totalling €38m incl existing + co-investor Lundbeckfonden Emerge |
2018-03-23 |
![[LSS] Life-Sciences-Scandinavia.com - The Scandinavian Life Sciences Web Portal](/images/basics/lss-life-sciences-scandinavia-portal-logo.svg){kind=logo}
1 2 3 4 5 6 7 8 9 10 11 
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
